Extended-release tablets to treat schizophrenia approved by KFDA

Published: 2007-12-20 06:57:00

Updated: 2007-12-20 06:57:00

The Korea Food and Drug Administration has approved Invega (paliperidone) extended-release tablets, a new atypical antipsychotic, for the treatment of schizophrenia, a spokesperson at Janssen Korea said.

The once-daily oral medication is specifically designed to deliver paliperidone the activ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK